Testing different doses of a drug to prevent graft-versus-host disease in stem cell transplant
Part of Blood & lymphatic clinical trials.
This trial is for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a half-matched donor. It compares two different doses of a medicine that helps prevent the donor cells from attacking the body (graft-versus-host disease).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 to 65 years old.
- You must have acute myeloid leukemia, acute lymphoblastic leukemia in remission, or myelodysplastic syndrome requiring a stem cell transplant.
- You must be getting a stem cell transplant from a half-matched (haploidentical) donor.
- You must be well enough to perform daily activities (ECOG score 0-2).
- You cannot be pregnant or breastfeeding.
- You cannot have had a prior stem cell or organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach to using ATG (a medicine that reduces immune rejection) in patients receiving stem cell transplants from unrelated donors for blood cancers. The goal is to improve transplant success while reducing side effects by tailoring ATG doses to individual patients.
This trial tests whether giving anti-thymocyte globulin (ATG) based on a person's own body chemistry can reduce side effects and improve outcomes in stem cell transplants. It is for people with certain blood cancers who are in their first or second remission.
This trial compares two drugs, ATLG and ATG, to see which one helps rebuild the immune system better after a stem cell transplant for blood cancer. It aims to improve recovery and reduce complications.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
This trial tests a two-step use of ATG (a drug that calms immune cells) to help prevent graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from a donor. It may be an option for people with certain blood cancers or disorders who are getting a strong, marrow-clearing transplant.
This trial tests a personalized dosing method for a medicine called ATG, which helps prevent your body from rejecting a donor stem cell transplant. It is for people with blood cancers who need a transplant from an unrelated donor.
Hear when a new Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.